Xenohormetic Phytochemicals Inhibit Neovascularization in Microphysiological Models of Vasculogenesis and Tumor Angiogenesis. 2024

G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
Department of Biomedical Engineering, Tulane University, New Orleans, LA, 70118, USA.

Xenohormesis proposes that phytochemicals produced to combat stressors in the host plant exert biochemical effects in animal cells lacking cognate receptors. Xenohormetic phytochemicals such as flavonoids and phytoalexins modulate a range of human cell signaling mechanisms but functional correlations with human pathophysiology are lacking. Here, potent inhibitory effects of grapefruit-derived Naringenin (Nar) and soybean-derived Glyceollins (Gly) in human microphysiological models of bulk tissue vasculogenesis and tumor angiogenesis are reported. Despite this interference of vascular morphogenesis, Nar and Gly are not cytotoxic to endothelial cells and do not prevent cell cycle entry. The anti-vasculogenic effects of Glyceollin are significantly more potent in sex-matched female (XX) models. Nar and Gly do not decrease viability or expression of proangiogenic genes in triple negative breast cancer (TNBC) cell spheroids, suggesting that inhibition of sprouting angiogenesis by Nar and Gly in a MPS model of the (TNBC) microenvironment are mediated via direct effects in endothelial cells. The study supports further research of Naringenin and Glyceollin as health-promoting agents with special attention to mechanisms of action in vascular endothelial cells and the role of biological sex, which can improve the understanding of dietary nutrition and the pharmacology of phytochemical preparations.

UI MeSH Term Description Entries

Related Publications

G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
February 2004, Seminars in thrombosis and hemostasis,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
May 2003, Nagoya journal of medical science,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
April 2001, Laboratory investigation; a journal of technical methods and pathology,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
May 1999, The Journal of clinical investigation,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
September 2000, Herz,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
September 1999, The Journal of nutrition,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
October 2013, Experimental cell research,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
June 2007, Neurological research,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
December 2003, Journal of UOEH,
G Wills Kpeli, and K Michael Conrad, and William Bralower, and C Ethan Byrne, and Stephen M Boue, and Matthew E Burow, and Mark J Mondrinos
January 2004, Cancer treatment and research,
Copied contents to your clipboard!